The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company, with partial American and British roots. It is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue.
Company profile
Ticker
TAK, TAK-MM
Exchange
Website
CEO
Christophe Weber
Employees
Location
Industry (SIC)
SEC CIK
TAK stock data
Latest filings (excl ownership)
6-K
Current report (foreign)
15 Apr 24
6-K
Current report (foreign)
27 Mar 24
6-K
Current report (foreign)
9 Feb 24
6-K
Current report (foreign)
2 Feb 24
6-K
Current report (foreign)
1 Feb 24
6-K
Current report (foreign)
1 Feb 24
6-K
Current report (foreign)
16 Jan 24
6-K
Current report (foreign)
14 Dec 23
6-K
Current report (foreign)
30 Nov 23
6-K
Current report (foreign)
13 Nov 23
Latest ownership filings
SC 13D/A
Phathom Pharmaceuticals, Inc.
10 Apr 24
SC 13D/A
Phathom Pharmaceuticals, Inc.
1 Apr 24
SC 13G/A
BlackRock Inc.
6 Feb 24
SC 13G/A
Sumitomo Mitsui Trust Holdings, Inc.
5 Feb 24
4
Phathom Pharmaceuticals, Inc.
25 Jan 24
SC 13D/A
Phathom Pharmaceuticals, Inc.
25 Jan 24
SC 13G
Equillium, Inc.
19 Jan 24
144
Notice of proposed sale of securities
10 Jul 23
144
Notice of proposed sale of securities
10 Jul 23
144
Notice of proposed sale of securities
10 Jul 23
Financial summary
Quarter (USD) | Mar 23 | Mar 22 | Mar 21 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Mar 23 | Mar 22 | Mar 21 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q4 2023
4.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 246 |
Opened positions | 41 |
Closed positions | 98 |
Increased positions | 50 |
Reduced positions | 99 |
13F shares | Current |
---|---|
Total value | 810.21 bn |
Total shares | 152.57 mm |
Total puts | 0.00 |
Total calls | 451.50 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
CMTDF Sumitomo Mitsui Trust | 87.40 mm | $0.00 |
Capital Research Global Investors | 14.30 mm | $204.03 bn |
Mondrian Investment Partners | 8.17 mm | $116.55 bn |
MS Morgan Stanley | 4.85 mm | $69.17 bn |
GS Goldman Sachs | 4.30 mm | $61.40 bn |
Renaissance Technologies | 3.33 mm | $47.48 mm |
Brandes Investment Partners | 2.65 mm | $37.83 bn |
MCQEF Macquarie | 2.45 mm | $34.90 bn |
FMR | 2.18 mm | $31.09 bn |
Arrowstreet Capital, Limited Partnership | 1.91 mm | $27.23 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
24 Jan 24 | Takeda Pharmaceutical | Common Stock | Sell | Dispose S | No | No | 8.1 | 3,703,703 | 30.00 mm | 3,755,583 |
17 Apr 23 | Takeda Pharmaceutical | Series A Convertible Preferred Stock Common Stock | Other | Dispose J | Yes | No | 40.08 | 1,000,000 | 40.08 mm | 0 |
30 Nov 22 | Takeda Pharmaceutical | Common Stock | Acquire X | Yes | No | 0 | 5,883,500 | 0.00 | 6,724,000 | |
30 Nov 22 | Takeda Pharmaceutical | Warrant Common Stock | Dispose X | Yes | No | 0.0001 | 5,883,500 | 588.35 | 0 |
News
Reported Earlier, Takeda Announces U.S. FDA Approval Of ENTYVIO Subcutaneous Administration For Maintenance Therapy In Moderately To Severely Active Crohn's Disease
19 Apr 24
Takeda Announces Approval Of ADZYNMA Intravenous Injection 1500 In Japan For Patients With Congenital Thrombotic Thrombocytopenic Purpura
26 Mar 24
Takeda Announces U.S. FDA Approval Of Supplemental New Drug Application For ICLUSIG In Adult Patients With Newly Diagnosed Ph+ ALL
19 Mar 24
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders, Financial Terms Undisclosed
19 Mar 24
Takeda Announces Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079) For Primary Immune Thrombocytopenia
13 Mar 24
Press releases
U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease
18 Apr 24
Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE
27 Mar 24
Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
26 Mar 24
Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia
13 Mar 24
Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas
26 Feb 24